Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

BACKGROUND: Acalabrutinib is a selective, covalent Bruton tyrosine-kinase inhibitor with activity in chronic lymphocytic leukaemia. We compare the efficacy of acalabrutinib with or without obinutuzumab against chlorambucil with obinutuzumab in patients with treatment-naive chronic lymphocytic leukae...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet
Main Authors: Sharman, Jeff P, Egyed, Miklos, Jurczak, Wojciech, Skarbnik, Alan, Pagel, John M, Flinn, Ian W, Kamdar, Manali, Munir, Talha, Walewska, Renata, Corbett, Gillian, Fogliatto, Laura Maria, Herishanu, Yair, Banerji, Versha, Coutre, Steven, Follows, George, Walker, Patricia, Karlsson, Karin, Ghia, Paolo, Janssens, Ann, Cymbalista, Florence, Woyach, Jennifer A, Salles, Gilles, Wierda, William G, Izumi, Raquel, Munugalavadla, Veerendra, Patel, Priti, Wang, Min Hui, Wong, Sofia, Byrd, John C
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8151619/
https://ncbi.nlm.nih.gov/pubmed/32305093
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(20)30262-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados